

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**MTA Bisphosphonates for preventing osteoporotic fragility
fractures**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was raised during the scoping process that some groups will have difficulty adhering to the complex instructions for taking oral bisphosphonates and their benefit from these treatments may be compromised. For example, people with dementia, learning disabilities; those unable to remain upright for the specified time period; and patients in whom oral bisphosphonates might be contraindicated such as those with oesophageal stricture.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The people in this group may be considered disabled, and therefore this represents a group protected by the equality legislation. The approach taken in NICE Technology Appraisals 160 and 161, which are being partly updated through this MTA, should continue to be applied. That is, that the Committee should consider those who are unable to comply with the recommended treatment in its decision making.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes were required to the scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders have been identified.

Approved by Associate Director (name): Elisabeth George...

Date: 20/08/2014